Advertisement

Systemic Chemotherapy in Advanced Head and Neck Cancer

  • Franco M. Muggia
  • Marcel Rozencweig
Part of the Developments in Oncology book series (DION, volume 2)

Abstract

The management of head and neck cancer will become an increasingly important problem for medical oncologists. Currently, chemotherapy is generally employed for tumors that are beyond the reach of surgery and radiotherapy. However, although a number of active compounds are available for use, the rapidly declining performance status of the patients and the lack of clearly evaluable lesions at this advanced stage of disease often hamper the rational administration of cytotoxic agents. For these reasons, chemotherapy is likely to become a common procedure during the initial phases of treatment over the next few years. As will be pointed out later, trials are already underway to define the role of chemotherapy under these favorable circumstances, termed the “initial curative approach”.

Keywords

Clin Oncol Neck Cancer Combination Chemotherapy Advanced Head Advanced Squamous Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Papac, RJ, EM Jacobs, LV Foye Jr., et al, Systemic therapy with amethopterin in squamous carcinoma of the head and neck. Cancer Chemother Rep 32: 47–54, 1963PubMedGoogle Scholar
  2. 2.
    Lane, M, JE Moore, III, H Levin, et al, Methotrexate therapy for squamous cell carcinomas of the head and neck. JAMA 204: 561–564, 1968PubMedCrossRefGoogle Scholar
  3. 3.
    Leone. LA, MM Albala, VB Rege, Treatment of carcinoma of the head and neck with intravenous methotrexate. Cancer 21: 828–831, 1968CrossRefGoogle Scholar
  4. 4.
    Levitt, M, MB Mosher, RC DeConti, et al, Improved therapeutic index of methotrexate with “leucovorin rescue”. Cancer Res 33: 1729–1734, 1973PubMedGoogle Scholar
  5. 5.
    Goldin, A, JM Venditti, SR Humphreys, et al, Studies on the management of mouse leukemia (L1210) with antagonists of folic acid. Cancer Res 15: 742–747, 1955PubMedGoogle Scholar
  6. 6.
    Von Hoff, DD, M Rozencweig, AC Louie, et al, “Single”-agent activity of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 62: 233–235, 1978Google Scholar
  7. 7.
    DeConti, RC, Phase III comparison of methotrexate with leucovorin vs methotrexate alone vs a combination of methotrexate plus leucovorin, cyclophosphamide and cytosine arabinoside in head and neck cancer. Prodeed Am Soc Clin Oncol 17: 248, 1976Google Scholar
  8. 8.
    Turrisi, AT, III, M Rozencweig, DD Von Hoff, et al, the role of bleomycin in the treatment of advanced head and neck cancer. In: Bleomycin: Current Status and New Developments, Carter, SK, ST Crooke, H Umezawa (eds), New York, Academic Press, pp. 151–163, 1978Google Scholar
  9. 9.
    Hainan, KE, NM Bleehen, TB Brewin, et al, Early clinical experience with bleomycin in the United Kingdom in series of 105 patients. Brit Med J 4: 635–638, 1972.CrossRefGoogle Scholar
  10. 10.
    Bonadonna, G, M De Lena, S Monfardini, et al, Clinical trials with bleomycin in lymphomas and in solid tumors. Europ J Cancer 8: 205–215, 1972Google Scholar
  11. 11.
    Haas, CD, CA Coltman Jr., JA Gottlieb, et al, Phase II evaluation of bleomycin. A Southwest Oncology Group study. Cancer 38: 8–12, 1976PubMedCrossRefGoogle Scholar
  12. 12.
    Clinical Screening Cooperative Group of the European Organization for Research on Treatment of Cancer: Study of the clinical efficiency of bleomycin in human cancer. Brit Med J 2: 643–645, 1970CrossRefGoogle Scholar
  13. 13.
    Yagoda, A, B Mukherji, C Young, et al, Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med 77: 861–870, 1972PubMedGoogle Scholar
  14. 14.
    Durkin, WJ, AP Pugh, E Jacobs, et al, Bleomycin (NSC-125066) therapy of responsive solid tumors. Oncology 33: 260–264, 1976PubMedCrossRefGoogle Scholar
  15. 15.
    Barranco, SC, RM Humphrey, The effects of bleomycin on survival and cell progression in Chinese hamster cells in vitro. Cancer Res 31: 1218–1223, 1971PubMedGoogle Scholar
  16. 16.
    Frindel, E, E Malaise, M Tubiana, Cell proliferation kinetics in five human solid tumors. Cancer 22: 611–620, 1968PubMedCrossRefGoogle Scholar
  17. 17.
    Drewinko, B, JK Novak, SC Barranco, The response of human lymphoma cells in vitro to bleomycin and 1, 3-bís (2-chloroethyl)-1-nitrosourea. Cancer Res 32: 1206–1208, 1972PubMedGoogle Scholar
  18. 18.
    Takabe, Y, T Miyamoto, H Watanabe, et al, Bleomycin: mammalian cell lethality and cellular basis of optimal schedule. J Natl Cancer Inst 59: 1251–1255, 1977PubMedGoogle Scholar
  19. 19.
    Krakoff, IH, E Cvitkovic, V Currie, et al, Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer 40: 2927–2037, 1977CrossRefGoogle Scholar
  20. 20.
    Rosenberg, B, L Van Camp, T. Krigas, Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature (London) 205: 698–699, 1965CrossRefGoogle Scholar
  21. 21.
    Rozencweig, M, DD Von Hoff, M Slavik, et al, Cis-diamminedichloroplatinum (II): a new anticancer drug. Ann Intern Med 86: 803–812, 1977PubMedGoogle Scholar
  22. 22.
    Muggia, FM, M Rozencweig, Platinum compounds in clinical oncology: review and future prospects. In: Advances in Cancer Chemotherapy, Carter, SK, A Goldin, K Kuretani, et al (eds), Baltimore, University Park Press, pp. 141–153, 1978Google Scholar
  23. 23.
    Hayes, DM, E Cvitkovic, RB Golbey, et al, High dose cis-platinum diammine dichloride. Cancer 39: 1372–1381, 1977PubMedCrossRefGoogle Scholar
  24. 24.
    Lippman, AJ, C Helson, J Helson, et al, Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 57: 191–200, 1973PubMedGoogle Scholar
  25. 25.
    Wittes, RE, E Cvitkovic, J Shah, et al, Cis-dichiorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 61: 359–366, 1977PubMedGoogle Scholar
  26. 26.
    Randolph, VL, RE Wittes, Weekly administration of cis-diamminedichloroplatinum (II) without hydration or osmotic diuresis. Europ J Cancer 14: 753–756, 1978Google Scholar
  27. 27.
    Panettiere, FJ, M Lane, D Lehane, Effectiveness of a new outpatient program utilizing CACP in the chemotherapy of advanced epidermoid head and neck tumors. A SWOG study, Proceed Am Soc Clin Oncol 19: 410, 1978Google Scholar
  28. 27.
    Panettiere, FJ, M Lane, D Lehane, Effectiveness of a new outpatient program utilizing CACP in the chemotherapy of advanced epidermoid head and neck tumors. A SWOG study, Proceed Am Soc Clin Oncol 19: 410, 1978Google Scholar
  29. 29.
    Livingston, R, S Carter, Single Agents in Cancer Chemotherapy, New York, Plenum Press, 1970Google Scholar
  30. 30.
    Smart, CR, DB Rochlin, AM Nahum, et al, Clinical experience with vinblastine sulfate (NSC-49842) in squamous cell carcinoma and other malignancies. Cancer Chemother Rep 34: 31–45, 1963Google Scholar
  31. 31.
    Livingston, RB, LH Einhorn, MA Burgess, et al, Advances in treatment of recurrent and disseminated squamous carcinoma of the lung, head and neck. In: Cancer Chemotherapy, Chicago, Yearbook Medical Publishers, pp. 233–249, 1975Google Scholar
  32. 32.
    Livingston, RB, GP Bodey, JA Gottlieb, et al, Kinetic scheduling of vincristine (NSC-67574) and bleomycin (NSC-125066) in patients with lung cancer and other malignant tumors. Cancer Chemother Rep 57: 219–224, 1973PubMedGoogle Scholar
  33. 33.
    Dowell, KE, DM Armstrong, JB Aust, et al, Systemic chemotherapy of advanced head and neck malignancies. Cancer 35: 1116–1120, 1975PubMedCrossRefGoogle Scholar
  34. 34.
    Knight, EW, J Horton, C Reilly, et al, A comparison of weekly vs 3-week course adriamycin in solid tumors. Proceed Am Assoc Cancer Res 13: 92, 1972Google Scholar
  35. 35.
    Benjamin, RS, PH Wiernik, NR Bachur, Adriamycin chemotherapy. Efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33: 19–27, 1974PubMedCrossRefGoogle Scholar
  36. 36.
    Bonadonna, G, G Beretta, G Tancini, et al, Adriamycin (NSC-123127) studies at the Istituto Nazionale Tumori, Milan. Cancer Chemother Rep 6: 231–245, 1975Google Scholar
  37. 37.
    Krakoff, IH, Adriamycin (NSC-123127) studies in adult patients. Cancer Chemother Rep 6: 253–257, 1975Google Scholar
  38. 38.
    Rozencweig, M, DD Von Hoff, FM Muggia, Investigational chemotherapeutic agents in head and neck cancer. Sem Oncol 4: 425–429, 1977Google Scholar
  39. 39.
    Alberto, P, R Peytremann, R Medenica, et al, Clinical experience with a combination of DDMP, a diaminopyrimidine, and folinic acid (CF). Proceed Am Soc Clin Oncol 19: 346, 1978Google Scholar
  40. 40.
    Medenica, R, P Alberto, W Lehmann, Traitement des carcinomes epidermoides oro-pharyngo-larynges dissemines par combinaison de methotrexate et de bleomycine a petites doses. Schewiz Med Woschr 106: 799802, 1976Google Scholar
  41. 41.
    Bonadonna, G, G Tancini, E Bajetta, Controlled studies with bleomycin in solid tumors and lymphomas. Prog Biochem Pharmacol 11: 172–184, 1976PubMedGoogle Scholar
  42. 42.
    Broquet, MA, E Jacot-Descombe, A Montandon, et al, Traitement des carcinomes epidermoides oto-pharyngo-larynges par combinaision de methotrexate et de bleomycine. Schweiz Med Woschr 104: 18–22, 1974Google Scholar
  43. 43.
    Yagoda, A, AJ Lippman, RJ Winn, et al, Combination chemotherapy with bleomycin (BLM) and methotrexate (MIX) in patients with advanced epidermoid carcinomas. Proceed Am Soc Clin Oncol 16: 247, 1975Google Scholar
  44. 44.
    Lokich, JJ, E Frei III, Phase II study of concurrent methotrexate and bleomycin chemotherapy. Cancer Res 34: 2240–2242, 1974PubMedGoogle Scholar
  45. 45.
    Mosher, MB, RC DeConti, JR Bertino, Bleomycin therapy in advanced Hodgkin’s disease and epidermoid cancers. Cancer 30: 56–60, 1972PubMedCrossRefGoogle Scholar
  46. 46.
    Price, LA, BT Hill, AH Calvert, et al, Kinetically-based multiple drug treatment for advanced head and neck cancer. Brit Med J 3: 10–11, 1975PubMedCrossRefGoogle Scholar
  47. 47.
    Pouillart, P, G Mathe, Bleomycin in rational combinations of chemotherapy. GANN monograph on cancer research No 19, Fundamental and clinical studies of bleomycin, Univ Tokyo Press, pp. 279–283, 1976Google Scholar
  48. 48.
    Ratkin, GA, CA Brown, JH Ogura, Combination chemotherapy in head and neck cancer. Proceed Am Soc Clin Oncol 19: 330, 1978Google Scholar
  49. 49.
    Costanzi, JJ, D Loukas, RG Gagliano, et al, Intravenous bleomycin infusion as a potential synchronizing agent in human disseminated malignancies. A preliminary report. Cancer 38: 1503–1506, 1976PubMedCrossRefGoogle Scholar
  50. 50.
    Stathopoulas, G, E Wiltshaw, LA Price, Quadruple chemotherapy in advanced squamous cell carcinoma of the head and neck. Brit J Clin Pract 30: 188–189, 1976Google Scholar
  51. 51.
    Cortes, EP, VC Amin, R Khafif, et al, Bleomycin (B) infusion with cyclophosphamide (C), methotrexate (M) and 5-fluorouracil (F) in previously irradiated head and neck cancer. Proceed Am Assoc Cancer Res 19: 140, 1978Google Scholar
  52. 52.
    Livingston, RB, LH Einhorn, MA Burgess, et al, Sequential combination chemotherapy for advanced, recurrent squamous carcimona of the head and neck. Cancer Treat Rep 60: 103–105, 1976PubMedGoogle Scholar
  53. 53.
    Wittes, RE, RH Spiro, J Shah, et al, Chemotherapy of head and neck cancer: combination treatment with cyclophosphamide, adriamycin, methotrexate and bleomycin. Med Ped Oncol 3: 301–309, 1977CrossRefGoogle Scholar
  54. 54.
    Murphy, WK, RB Livingston, E Gehan, et al, Sequential chemotherapy in the treatment of cancer of the head and neck. Proceed Am Assoc Cancer Res 18: 190, 1977Google Scholar
  55. 55.
    Wittes, RE, F Brescia, CW Young, et al, Combination chemotherapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology 32: 202–207, 1975PubMedCrossRefGoogle Scholar
  56. 56.
    Randolph, VL A Vallejo, RH Spiro, et al, Combination therapy of advanced head and neck cancer: induction of remissions with diamminedichloroplatinum (II), bleomycin, and radiation therapy. Cancer 41: 460–467, 1978PubMedCrossRefGoogle Scholar
  57. 57.
    Hong, WK, R Bhutani, S Shapshay, et al, Induction chemotherapy of advanced unresectable head and neck cancer with cis-diammine dichloro platinum (II) (DDP) and bleomycin. Proceed Am Soc Clin Oncol 19: 321, 1978Google Scholar
  58. 58.
    Bianco, AA, SG Taylor IV, SD Reich, et al, Combination chemotherapy in head and neck squamous cancer. Proceed Am Soc Clin Oncol 19: 380, 1978Google Scholar
  59. 59.
    Bonomi, PD, J Mladineo, GD Wilbanks, et al, Phase II trial of adriamycin and cis-diamminedichloroplatinum (CACP) in advanced squamous cell carcinoma (SCC). Proceed Am soc Clin Oncol 18: 311, 1977Google Scholar
  60. 60.
    Amer, MH, R Izbicki, M Al-Sarraf, Combination of high dose cis-platinum, oncovin and bleomycin (COB) in treatment of patients with advanced head and neck cancer. Proceed Am Soc Clin Oncol 19: 312, 1978Google Scholar
  61. 61.
    Kaplan, BH, SE Vogl, Methotrexate (M), bleomycin (B) and diamminedichloroplatinum (D) in squamous cancers (Sq Ca) of the head and neck, cervix and other sites. Proceed Am Soc Clin Oncol 19: 323, 1978Google Scholar
  62. 62.
    Caradonna, R, W Paladine, J Goldstein, et al Combination chemotherapy with high dose cis-diamminedichloroplatinum (II) (CDDP), methotrexate (MTX), and bleomycin (Bleo) for epidermoid carcinoma of the head and neck. Proceed Am Soc Clin Oncol 19: 401, 1978Google Scholar
  63. 63.
    Elias, EG, PB Chretien, E Monnard, et al, Combination chemotherapy in advanced squamous cell carcinoma of the head and neck. Proceed Am Soc Clin Oncol 19: 376, 1978Google Scholar
  64. 63.
    Elias, EG, PB Chretien, E Monnard, et al, Combination chemotherapy in advanced squamous cell carcinoma of the head and neck. Proceed Am Soc Clin Oncol 19: 376, 1978Google Scholar
  65. 65.
    Goldsmith, MA, SK Carter, The integration of chemotherapy into a combined modality approach to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev 2: 137–158, 1975PubMedCrossRefGoogle Scholar
  66. 66.
    Lustig, RA, PA DeMare, S Kramer, Adjuvant methotrexate in the radiotherapeutic management of advanced tumors of the head and neck. Cancer 37: 2703–2708, 1976PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers bv, The Hague 1980

Authors and Affiliations

  • Franco M. Muggia
    • 1
  • Marcel Rozencweig
    • 1
  1. 1.National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations